Method for screening anticancer agent inhibiting binding of AIMP2-DX2 and HSP70

A method for screening an anti-cancer agent, the method comprising the steps of:

• (a) contacting AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of a test substance;
• (b) measuring a binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of the test substance;
• (c) comparing the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence of the test substance with the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the absence of the test substance to determine a change in the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof by the test substance;
• (d) selecting the test substance that reduces the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof;
• and
• (e) verifying an anti-cancer activity of the selected test substance in cells or animals, wherein the cancer is a cancer expressing AIMP2-DX2, wherein AIMP2-DX2 comprises the amino acid sequence of SEQ ID NO:
• 1 and the fragment of AIMP2-DX2 comprises amino acid residues 1 to 87 of SEQ ID NO:
• 1, wherein the fragment of AIMP2-DX2 has a binding affinity to HSP70, and wherein HSP70 comprises the amino acid sequence of SEQ ID NO:
• 3, and the fragment of HSP70 consists of amino acid residues 385 to 536 of SEQ ID NO:
• 3, wherein the fragment of HSP70 has a binding affinity to AIMP2-DX2.